PatientsVille.com Logo

HAEMORRHAGE and Dopamine

PatientsVille

HAEMORRHAGE Symptoms and Causes

A stroke is a medical emergency. There are two types - ischemic and hemorrhagic. Hemorrhagic stroke is the less common type. It happens when a blood vessel breaks and bleeds into the brain. Within minutes, brain cells begin to die. Causes include a bleeding aneurysm, an arteriovenous malformation (AVM), or an artery wall that breaks open.

Symptoms of stroke are

  • Sudden numbness or weakness of the face, arm or leg (especially on one side of the body)
  • Sudden confusion, trouble speaking or understanding speech
  • Sudden trouble seeing in one or both eyes
  • Sudden trouble walking, dizziness, loss of balance or coordination
  • Sudden severe headache with no known cause

It is important to treat strokes as quickly as possible. With a hemorrhagic stroke, the first steps are to find the cause of bleeding in the brain and then control it. Surgery may be needed. Post-stroke rehabilitation can help people overcome disabilities caused by stroke damage.

National Institute of Neurological Disorders and Stroke

Check out the latest treatments for HAEMORRHAGE

HAEMORRHAGE treatment research studies

Dopamine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Dopamine Side Effects

Renal Failure (24)
Injury (23)
Unevaluable Event (21)
Fear (20)
Pain (19)
Renal Injury (18)
Death (17)
Emotional Distress (16)
Renal Impairment (15)
Anxiety (15)
Multi-organ Failure (14)
Stress (14)
Hypotension (11)
Device Failure (11)
Anhedonia (10)
Blood Pressure Decreased (10)
Device Malfunction (9)
Cardiac Arrest (9)
Depression (7)
Cardio-respiratory Arrest (5)
Loss Of Consciousness (5)
Incorrect Dose Administered (5)
Electrocardiogram St Segment Elevation (4)
Hypernatraemia (4)
Cerebrovascular Accident (4)
Bradycardia (4)
Renal Failure Acute (4)
Myocardial Infarction (4)
Ventricular Fibrillation (4)
Ventricular Tachycardia (4)
Pulse Absent (4)
Acidosis (3)
Accidental Overdose (3)
Acute Respiratory Distress Syndrome (3)
Blood Pressure Systolic Decreased (3)
Choreoathetosis (3)
Condition Aggravated (3)
Blood Pressure Immeasurable (3)
Atrial Fibrillation (3)
Confusional State (3)
Encephalitis (3)
Depressed Level Of Consciousness (3)
Tachycardia (3)
Hypertension (3)
Metabolic Acidosis (3)
Rhabdomyolysis (3)
Mitral Valve Incompetence (3)
Nausea (2)
Pancytopenia (2)
Nervousness (2)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

HAEMORRHAGE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage
Condition: Acute Bleeding Esophageal Varices
Interventions: Device: Self-expanding mesh-metal oesophageal stent (SEMS);   Other: Standard Therapy
Outcome Measures: Failure to Control Bleeding;   Absence of Bleeding at 14 and 42 days;   Participant Survival;   Absence of Stent Migration;   Requirement for Blood products;   Requirement for Analgesia and Sedation whilst Stent in in situ;   Presence of Thoracic Pain or Dysphagia;   Length of Intensive Care Unit and Total Hospital Stay;   Requirement for additional endoscopic therapy or salvage therapy (such as TIPS);   Repeated presentation with variceal bleeding within 6 months
2 Recruiting Bilateral Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery
Condition: Postpartum Haemorrhage
Intervention: Procedure: bilateral uterine compression
Outcome Measures: Blood loss 500 ml or more after enrolment;   Blood loss 1000 ml or more after enrolment;   Use of additional uterotonics or other procedures;   Blood transfusion
3 Recruiting Association Between Haptoglobin Genotype and Brain Swelling
Condition: Intracerebral Hemorrhage
Intervention: Other: Intracerebral Hemorrhage
Outcome Measure: Perihematomal Edema Volume
4 Not yet recruiting Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage
Condition: Postpartum Haemorrhage
Intervention:
Outcome Measures: Early haemostatic predictors of major obstetric Haemorrhage;   Evaluation of ROTEM-based MOH prediction scores as alternative to traditional haemostatic parameters;   Incidence of underlying bleeding disorders in patients with MOH;   Predictive value bleeding score in pregnancy for MOH
5 Recruiting Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
Condition: Postpartum Hemorrhage
Interventions: Drug: carbetocin;   Drug: misopristol;   Drug: oxytocin
Outcome Measures: control of postpartum hemorrhage;   time of control of bleeding, amount of blood loss till control of bleeding, changes in the hemoglobin and hematocrite levels, use of additional uterotonic drugs, necessity for surgical intervention, and the rate of complications.
6 Recruiting PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
Conditions: Brain Ischemia;   Intracranial Hemorrhages
Interventions: Drug: Cilostazol;   Drug: Probucol;   Drug: Aspirin;   Drug: placebo of cilostazol;   Drug: placebo of aspirin;   Device: ankle-brachial index (ABI);   Device: intima-medial thickness (IMT);   Device: new asymptomatic brain hemorrhage;   Device: new ischemic lesions on follow-up FLAIR images
Outcome Measures: time to first occurrence of cerebral hemorrhage;   time to first occurrence of cardiovascular events;   Time to the first occurrence of stroke;   Time to the first occurrence of ischemic stroke;   Time to the first occurrence of myocardial infarction;   Time to the first occurrence of other designated vascular events;   time to occurrence of major bleeding complications;   occurrence of new microbleedings or asymptomatic new hemorrhage on GRE image;   new ischemic lesions on FLAIR images;   change of Ankle-Brachial Index;   change of intima-medial thickness;   time to occurrence of any death
7 Not yet recruiting Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
Condition: Postpartum Hemorrhage
Interventions: Procedure: Routine care;   Device: Bakri balloon
Outcome Measures: The % of patients requiring invasive measures for postpartum hemorrhage control.;   The total cost (€) associated with the postpartum hemorrhage management strategy.;   The delay required to stop bleeding post-delivery (min);   The delay required to stop bleeding post-diagnosis (min);   The percentage of patients still bleeding 30 minutes after sulprostone injection;   Blood loss (ml) 30 minutes after diagnosis;   Blood loss (ml) 1 hour after diagnosis;   Blood loss (ml) 2 hours after diagnosis;   Blood loss (ml) 24 hours after diagnosis;   Blood pressure;   Heart rate;   The % of patients requiring blood transfusion.;   The % of patients requiring intravenous iron.;   The quantity of packed red cells, platelet concentrate and fresh frozen plasma consumed;   Fibrinogen (g / l);   Hematocrit (%);   Hemoglobin (g/dl);   Prothrombin (%);   Activated partial thromboplastin time (s);   Length of hospital stay (days);   Length of ICU stay;   Antimullerian hormone level;   Amenorrhea at 3 months? yes/no;   The presence of adhesions detected at hysteroscopy;   pain will be assessed in both arms via a visual analog scale, duration, location, and use of analgesics;   temperature (°C);   FSFI questionnaire (Female Sexual Function Index);   Doppler ultrasound: intra-uterine pressure;   Doppler ultrasound: thickness of the uterine wall;   Doppler ultrasound: inversed diastolic flow;   Doppler ultrasound: intraluminal pressure;   Doppler ultrasound: uterine artery perfusion pressure;   Doppler ultrasound: uterine artery pulsatility index;   IES-R scale (symptoms of post-traumatic stress)
8 Recruiting Observational Study in Preterm Infants With Intracranial Hemorrhage
Conditions: Intracranial Hemorrhage;   Intraventricular Hemorrhage;   Cerebral Hypoxia
Intervention:
Outcome Measures: Progression of cerebral oxygenation;   Progression of cerebral perfusion and function
9 Unknown  Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage
Condition: Postpartum Hemorrhage
Intervention: Drug: oxygen
Outcome Measures: The primary outcome was the amount of blood loss in the third and fourth stages of labor.;   incidences of Postpartum Haemorrhage (PPH) (≥500 ml)
10 Recruiting Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring
Conditions: Intraventricular Haemorrhage;   Pulmonary Haemorrhage
Intervention: Device: Coaguchek
Outcome Measures: major bleeding;   mortality
11 Recruiting Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage
Conditions: Intraventricular Hemorrhage;   Autoregulation
Interventions: Other: Hypercapnia;   Other: Normocapnia
Outcome Measures: The effect of hypercapnia vs. normocapnia on the development of Grade II-IV intraventricular hemorrhage/periventricular leukomalacia (severe brain injury) and/or death;   The effect of hypercapnia vs. normocapnia on the development of chronic lung disease (requirement of supplemental oxygen at 36 weeks corrected gestational age);   The effect of hypercapnia vs. normocapnia on abnormal results from MRIs;   The effect of hypercapnia vs. normocapnia on the development of pulmonary hemorrhage
12 Recruiting Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment
Conditions: Coronary Occlusion/Thrombosis;   Peptic Ulcer Hemorrhage
Intervention: Other: Screening for risk factors for ulcer bleeding
Outcome Measures: Admission for ulcer bleeding or haemorrhagic gastritis;   Compliance with antithrombotic medicine;   Identification of patients with Benefit of Proton pump inhibitor Prophylaxis;   Gastrointestinal bleeding;   Uncomplicated ulcers;   Death;   Acute coronary syndrome
13 Recruiting The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage;   Terson Syndrome;   CSF-proteines
Intervention:
Outcome Measures: Intracranial pressure (ICP) in mmH20;   Concentration of CSF-protein phospho-tau;   Concentration of CSF-protein amyloid-ß 40/42;   Delayed cerebral ischemia;   Clinically manifest vasospasm;   Re-bleed;   Surgery for refractory ICP (decompressive hemicraniectomy);   Necessity of CSF-shunt;   Opthalmologic exam
14 Recruiting Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients
Conditions: Aneurysmal Subarachnoid Heamorrhage;   Nontraumatic Subarachnoid Haemorrhage
Intervention:
Outcome Measure: Incidence of cardiac failure and the impact of cardiac problems on morbidity
15 Recruiting Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage
Condition: Non Traumatic Primary Intracerebral Hemorrhage
Intervention: Other: Pet AV-45 (Florbetapir F 18) Cerebral Amyloid imaging
Outcome Measures: Pet-AV45 cortical binding;   cerebral microbleeds number and distribution on T2EG MRI sequence;   White Matter Lesions Volume on 3D-FLAIR MRI sequence;   Cortical thickness and hippocampal volume on 3D-T1 MRI sequence;   Neuropsychological performances
16 Recruiting Remote Ischemic Preconditioning in Subarachnoid Hemorrhage
Conditions: Subarachnoid Hemorrhage, Aneurysmal;   Subarachnoid Hemorrhage;   Cerebral Vasospasm;   Intracranial Aneurysm
Intervention: Procedure: Remote ischemic preconditioning
Outcome Measures: Occurrence of neurological events, or vasospasm;   Transcranial Doppler Measurements and metabolic assessment
17 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
Outcome Measures: Mean ETDRS visual acuity;   Percentage patients 15 letters or greater improvement in ETDRS visual acuity;   Percentage patients 0 letters or greater improvement in ETDRS visual acuity;   Percentage patients 15 letters or greater loss in ETDRS visual acuity;   Mean total area of macular Haemorrhage on colour fundus photography;   Greatest linear dimension of macular Haemorrhage on colour fundus photography;   Presence of subfoveal blood on colour fundus photography
18 Recruiting Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive
Conditions: Abnormal Uterine Bleeding, Unspecified;   Uterine Bleeding Heavy
Interventions: Drug: EE 30mcg/LNG 150mcg;   Drug: Placebo
Outcome Measures: Bleeding Improvement;   Adverse Events
19 Recruiting Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage
Condition: Postpartum Hemorrhage
Intervention: Drug: Oxytocin
Outcome Measures: Proportion of women with postpartum blood loss equal to or greater than 500 mL;   Mean postpartum blood loss;   Proportion of women with postpartum blood loss equal to or greater than 350 mL;   Proportion of women with postpartum blood loss equal to or greater than 1000 mL;   Mean change in hemoglobin pre-delivery to postpartum;   Time to delivery of placenta;   Administration of additional oxytocin, other uterotonics or other interventions such as blood transfusion or hysterectomy;   Side effects 1 hour postpartum
20 Not yet recruiting Continuous Monitoring of Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage
Condition: Intraparenchimal Cerebral Haemorrhage
Intervention:
Outcome Measure: evaluation of blood pressure varibility on clinical course in patients with cerebral Haemorrhage